A treat-and-extend regimen of intravitreal bevacizumab (Avastin, Genentech) produced "significant visual improvements" for eyes with neovascular age-related macular degeneration, according to an article published in the March issue of the American Journal of Ophthalmology.
A treat-and-extend regimen of intravitreal bevacizumab (Avastin, Genentech) produced “significant visual improvements” for eyes with neovascular age-related macular degeneration (AMD), according to an article published in the March issue of the American Journal of Ophthalmology.
Patients also had fewer office visits, ancillary tests, and intravitreal injections compared with a traditional pro re nata (PRN) approach, according to Gary Shienbaum, MD, and colleagues in the Retina Service at Wills Eye Institute of Thomas Jefferson University in Philadelphia.
“Our goal was to maintain an exudation-free macula while individualizing treatment, and thereby minimizing the total number of injections, office visits, and ancillary tests,” the authors stated. “Overall, patients experienced significant visual acuity improvements on par with the phase 3 ranibizumab studies but with fewer encounters, fewer treatments, and lower costs.”
The researchers identified patients diagnosed with neovascular AMD from 2006 through 2009 for their retrospective, interventional, consecutive case series. They included 74 eyes of 73 patients with treatment-naïve subfoveal choroidal neovascularization secondary to neovascular AMD, managed with a treat-and-extend regimen of intravitreal bevacizumab injections monthly.
The mean follow-up period was 1.41 years until no signs of macular hemorrhage were observed on slit-lamp biomicroscopic examination and no intraretinal or subretinal fluid was observed on optical coherence tomography (OCT).
Mean Snellen visual acuity improved significantly from 20/230 at baseline to 20/109 at 12 months (P<.001) and 20/106 at 24 months (P<.001). Mean OCT central retinal thickness decreased from 316 to 239 μm at 1 year of follow-up (P<.001). The mean number of injections during the first year was 7.94 and 5.60 between years 1 and 2.
In addition, the authors directly compared the medical costs of patients treated with intravitreal bevacizumab using a treat-and-extend regimen with those treated with intravitreal ranibizumab (Lucentis, Genentech) using a treat-and-extend regimen.
They found that the mean direct medical cost per patient treated with intravitreal bevacizumab during the first year was almost $3,500 compared with more than $16,000 for those treated with ranibizumab. And the mean direct medical costs per patient treated with intravitreal bevacizumab between years 1 and 2 was a little more than $1,800 compared with almost $14,000 for those treated with ranibizumab.
Although the authors state that the limitations of their study mean they cannot compare the effectiveness between bevacizumab and ranibizumab as a treatment regimen, they note that the study “demonstrates the favorable visual outcomes achieved using bevacizumab in a treat-and-extend regimen and highlights the need for future prospective, randomized controlled studies evaluating the efficacy of a treat-and-extend regimen versus monthly injections and traditional PRN regimens.”
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.